ストックスクリーナーアプリを入手
35.95
4.04%
1.395
アフターアワーズ：
35.95
-0.005
-0.01%
前日終値:
$34.56
開ける：
$34.87
24時間の取引高:
2.65M
Relative Volume:
1.58
時価総額：
$4.33B
収益：
$10.12M
当期純損益:
$-280.49M
株価収益率:
-12.44
EPS:
-2.89
ネットキャッシュフロー:
$-188.51M
1週間 パフォーマンス:
+7.23%
1か月 パフォーマンス:
+23.85%
6か月 パフォーマンス:
+12.64%
1年 パフォーマンス:
-22.56%
1日の値動き範囲:
$34.25
$36.03
1週間の範囲:
$32.72
$37.59
52週間の値動き範囲:
$21.51
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
名前
Avidity Biosciences Inc
セクター
電話
858-401-7900
住所
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
RNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
35.95 | 4.37B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.79 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-06-24 | 開始されました | Bernstein | Outperform |
| 2025-06-17 | 開始されました | Wolfe Research | Outperform |
| 2025-06-11 | 開始されました | Raymond James | Strong Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-20 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-09-24 | 開始されました | Goldman | Buy |
| 2024-08-28 | 開始されました | Barclays | Overweight |
| 2024-05-03 | 開始されました | BofA Securities | Buy |
| 2024-03-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-05-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-31 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Strong Buy |
| 2021-09-07 | 開始されました | Evercore ISI | Outperform |
| 2021-06-17 | 開始されました | Needham | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-07-07 | 開始されました | Cowen | Outperform |
| 2020-07-07 | 開始されました | Credit Suisse | Outperform |
| 2020-07-07 | 開始されました | SVB Leerink | Outperform |
| 2020-07-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Avidity Biosciences Inc (RNA) 最新ニュース
Trendline Breach Raises Concern for Avidity Biosciences Inc. InvestorsStable Entry High Return Opportunities in Focus - metal.it
Avidity Biosciences and the Potential for First-in-Class DM1 Therapy - AInvest
Avidity completes enrollment for phase 3 trial of DM1 treatment By Investing.com - Investing.com South Africa
Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission - Yahoo Finance
What is the dividend policy of Avidity Biosciences Inc. stockDiscover stocks with explosive upside potential - jammulinksnews.com
What are the technical indicators suggesting about Avidity Biosciences Inc.Capitalize on fast-growing stocks today - jammulinksnews.com
How volatile is Avidity Biosciences Inc. stock compared to the marketMaximize your returns with portfolio optimization - jammulinksnews.com
Should I hold or sell Avidity Biosciences Inc. stock in 2025Get alerts on the hottest market movers - jammulinksnews.com
How does Avidity Biosciences Inc. generate profit in a changing economyMassive stock growth - jammulinksnews.com
Is it the right time to buy Avidity Biosciences Inc. stockExpert guidance for superior capital growth - jammulinksnews.com
Why is Avidity Biosciences Inc. stock attracting strong analyst attentionMaximize gains with timely market signals - jammulinksnews.com
What institutional investors are buying Avidity Biosciences Inc. stockHigh-margin investment plays - jammulinksnews.com
What makes Avidity Biosciences Inc. stock price move sharplyUnlock exclusive stock analysis for investors - jammulinksnews.com
What are analysts’ price targets for Avidity Biosciences Inc. in the next 12 monthsDiscover stocks with superior performance - jammulinksnews.com
Avidity (RNA) Jumps 9.2% on Drug Candidate’s Breakthrough Therapy Designation - Insider Monkey
Avidity Biosciences shares climb after FDA grants Breakthrough Therapy designation - MSN
Is Avidity Biosciences Inc. a good long term investmentFree Stock Market Trend Analysis - PrintWeekIndia
Avidity’s Stock Surge: Time to Act? - timothysykes.com
What drives Avidity Biosciences Inc. stock priceFree Wealth Planning Blueprint - PrintWeekIndia
How Avidity Biosciences Inc. stock reacts to Fed policy changesFree Smart Trading Workshop - jammulinksnews.com
Avidity Biosciences shares rise 1.80% premarket after receiving FDA Breakthrough Therapy designation for DMD treatment. - AInvest
Avidity Biosciences Gains FDA Breakthrough Therapy Designation - TipRanks
Why Avidity Biosciences Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - beatles.ru
Avidity gets FDA breakthrough therapy status for DMD treatment - Seeking Alpha
FDA grants breakthrough therapy status to Avidity’s DMD drug By Investing.com - Investing.com Canada
Avidity Biosciences stock rises after FDA grants Breakthrough Therapy status - Investing.com Australia
Avidity Biosciences stock rises after FDA grants Breakthrough Therapy status By Investing.com - Investing.com India
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping - PR Newswire
What analysts say about Avidity Biosciences Inc. stockOutstanding capital appreciation - jammulinksnews.com
Avidity Biosciences Inc. Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com
Avidity Biosciences Inc (RNA) 財務データ
収益
当期純利益
現金流量
EPS
10.28%
2.59%
大文字化:
|
ボリューム (24 時間):